ArticleFrontiers in nutrition2026
Comparable disease course in pediatric celiac disease with or without endoscopic confirmation at high anti-TG2-IgA-antibody titers.
Article in Frontiers in nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The guidelines from the European Society for Pediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) enable the diagnosis of celiac disease (CD) omitting esophagogastroduodenoscopy (EGD) in patients with high anti-Transglutaminase 2 (TG2)-IgA-antibodies. However, there is uncertainty whether this approach is safe in terms of disease outcomes for all patients. Here, we aimed to investigate the course of anti-TG2-IgA-antibodies, symptomatic response, anthropometric measurements and routine laboratory values in CD patients presenting with high anti-TG2-IgA-antibodies diagnosed with or without EGD. Methods: We conducted a retrospective case-control study in two pediatric gastroenterology centers in Giessen and Marburg. CD patients presenting with high anti-TG2-IgA-antibodies (≥10× upper limit of normal) were included. Data were obtained from the routine medical documentation sheet at 0, 0.5, 1 and 2 years after diagnosis. Results: 48 patients (24 patients per group) were included. Both groups did not differ in sex or age distribution, symptom burden, comorbidities, weight and BMI z-scores or routine laboratory parameters at baseline. Decline of anti-TG2-IgA-antibodies was similar in both groups. Serological remission was achieved in 6% (without EGD) and 16% (with EGD) at 0.5 years and 26% and 41% at 1 year after diagnosis with no significant differences between the two groups. Symptom relief, weight and BMI z-scores as well as hemoglobin, ferritin and mean corpuscular volume did not differ depending on the mode of diagnosis. Conclusion: Our data confirm that the biopsy-sparing diagnostic algorithm is associated with similar serological and clinical outcomes in pediatric CD patients. Thus, our findings support the further application and implementation of the "non-biopsy approach."
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.